IL-1 contributes to the anti-cancer efficacy of ingenol mebutate

Loading...
Thumbnail Image
File version
Version of Record (VoR)
Author(s)
Le, TT
Skak, K
Schroder, K
Schroder, WA
Boyle, GM
Pierce, CJ
Suhrbier, A
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2016
Size
File type(s)
Location
License
http://creativecommons.org/licenses/by/4.0/
Abstract

Ingenol mebutate is approved for the topical treatment of actinic keratoses and may ultimately also find utility in treating skin cancers. Here we show that relapse rates of subcutaneous B16 melanoma tumours treated topically with ingenol mebutate were not significantly different in C57BL/6 and Rag1-/- mice, suggesting B and T cells do not play a major role in the anti-cancer efficacy of ingenol mebutate. Relapse rates were, however, significantly increased in MyD88-/- mice and in C57BL/6 mice treated with the anti-IL-1 agent, anakinra. Ingenol mebutate treatment induces a pronounced infiltration of neutrophils, which have been shown to have anti-cancer activity in mice. Herein we provide evidence that IL-1 promotes neutrophil recruitment to the tumour, decreases apoptosis of infiltrating neutrophils and increases neutrophil tumour killing activity. These studies suggest IL-1, via its action on neutrophils, promotes the anti-cancer efficacy of ingenol mebutate, with ingenol mebutate treatment causing both IL-1β induction and IL-1α released from keratinocytes.

Journal Title
PLoS One
Conference Title
Book Title
Edition
Volume
11
Issue
4
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© 2016 Le et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Item Access Status
Note
Access the data
Related item(s)
Subject
Oncology and carcinogenesis
Persistent link to this record
Citation
Le, TT; Skak, K; Schroder, K; Schroder, WA; Boyle, GM; Pierce, CJ; Suhrbier, A, IL-1 contributes to the anti-cancer efficacy of ingenol mebutate, PLoS One, 2016, 11 (4)
Collections